Indegene Share Price

NSE
INDGN •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Indegene
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
52W high on Oct 01, 2024
-14
TTM PE Ratio
Below industry Median
35.4
Price to Book Ratio
Below industry Median
5.8
Dividend yield 1yr %
0
TTM PEG Ratio

Indegene Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Indegene Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
720.4 Cr
686.8 Cr
676.5 Cr
673 Cr
673.41 Cr

Indegene Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021
2665.9 Cr
2364.1 Cr
1690.5 Cr
996.92 Cr

Indegene Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
109.7 Cr
91.7 Cr
87.7 Cr
94.8 Cr
98.5 Cr

Indegene Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021
336.7 Cr
266.1 Cr
162.82 Cr
185.88 Cr
Indegene Result Highlights
  • Indegene Ltd reported a 7.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 10.4%.

  • Its expenses for the quarter were up by 4.7% QoQ and 10.3% YoY.

  • The net profit increased 19.6% QoQ and increased 11.4% YoY.

  • The earnings per share (EPS) of Indegene Ltd stood at 4.5 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Indegene shareholding Pattern

Foreign Institutions
5%
Mutual Funds
1.6%
Domestic Institutions
4%
Public
91%
Foreign Institutions
4.8%
Mutual Funds
1.6%
Domestic Institutions
3.2%
Public
92%
Foreign Institutions
3.8%
Mutual Funds
2.3%
Domestic Institutions
3.8%
Public
92.4%

Indegene Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
14
5Day EMA
587.10
10Day EMA
597.60
12Day EMA
600.50
20Day EMA
607.90
26Day EMA
611.00
50Day EMA
618.20
100Day EMA
619.30
EMA
5Day SMA
586.40
10Day SMA
603.20
20Day SMA
614.20
30Day SMA
622.30
50Day SMA
612.20
100Day SMA
638.90
150Day SMA
628.00
SMA
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
381150 Rs
874341 Rs
Week Rs
191890 Rs
396160 Rs
Month Rs
201072 Rs
406198 Rs
Resistance & Support
581.00
Pivot
Resistance
First Resistance
596.65
Second Resistance
617.10
Third Resistance
632.75
Support
First Support
560.55
Second support
544.90
Third Support
524.45
Relative Strength Index
39.23
Money Flow Index
37.74
MACD
-10.54
MACD Signal
-5.49
Average True Range
25.36
Average Directional Index
19.78
Rate of Change (21)
-14.48
Rate of Change (125)
-2.42

Indegene Company background

Founded in: 1998
Indegene Limited was incorporated as Indegene Lifesystems Private Limited at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to Indegene Private Limited and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to Indegene Limited on November 17, 2022.The Company is a global provider of solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and healthcare organizations. It provide digitalled commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a digital first approach for optimizing the lastmile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analyticsin helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.The Company acquired Cult Health, a fullservice healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.The Company launched Invisage, an AIenabled hybrid omnichannel sales and marketing platform in 2023. The Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.In 2024, the Company acquired a controlling stake in Trilogy Writing Consulting GmbH.
Read More

Indegene FAQs

Indegene share price is ₹568.4 in NSE and ₹567.35 in BSE as on 17/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Indegene share price in the past 1-year return was 0. The Indegene share hit a 1-year low of Rs. 470.1 and a 1-year high of Rs. 736.3.

The market cap of Indegene is Rs. 13794.59 Cr. as of 17/2/2025 12:00:00 AM.

The PE ratios of Indegene is 78.37 as of 17/2/2025 12:00:00 AM.

The PB ratios of Indegene is 7.78 as of 17/2/2025 12:00:00 AM

The Mutual Fund Shareholding in Indegene was 1.64% at the end of 17/2/2025 12:00:00 AM.

You can easily buy Indegene shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -